Ascletis, a China-based biotechnology company focused on innovative drug development, received a US$20m investment from Goldman Sachs.
So far, Ascletis has completed two rounds of financing within the past two months. The first round of US$35m investment was led by C-Bridge Capital, Tasly Pharmaceutical and Pavilion Capital.
The company intends to use the funds to to strengthen R&D capacity, and broaden the scope of its R&D pipeline.
Led by Jinzi Wu, PhD., founder, President and CEO, Ascletis is a biotechnology company dedicated to discovering, developing and commercializing new treatments for infectious diseases and cancer. To date, the company owns four products that are in the clinical phase with proprietary intellectual property rights.
– ASC08, an HCV NS3/4A protease inhibitor licensed from Roche;
– ASC16, an HCV NS5A protease inhibitor licensed from Presidio Pharmaceuticals;
– ASC06, an RNAi therapeutic for the treatment of liver cancer licensed from Alnylam Pharmaceuticals; and
– ASC09, an HIV protease inhibitor licensed from Janssen.